VIA
NVO

Vident Investment Advisory’s Novo Nordisk NVO Stock Holding History

Vident Investment Advisory’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-23,464
Closed -$1.89M – 699
2023
Q2 		$1.89M Buy
23,464
+3,762
+19% +$307K 0.07% 322
2023
Q1 		$1.57M Buy
19,702
+6,808
+53% +$483K 0.05% 408
2022
Q4 		$873K Buy
+12,894
New +$756K 0.03% 521
2022
Q3 		– Sell
-4,978
Closed -$273K – 1251
2022
Q2 		$273K Buy
+4,978
New +$276K 0.01% 1047

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vident Investment Advisory's NVO Position: Q3 2023 in Review

Vident Investment Advisory sold out of Novo Nordisk (NVO) in Q3 2023, closing a stake of 23,464 shares — an estimated $1.89M sold.

Vident Investment Advisory first reported a position in NVO in Q2 2022 and held it in 4 quarters. The position peaked at $1.89M in Q2 2023. 1,307 funds tracked by Wall St. Rank hold NVO as of Q3 2023.

  • Vident Investment Advisory reported no remaining Novo Nordisk position as of Q3 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 23,464 Novo Nordisk shares in Q3 2023, an estimated $1.89M.
  • Vident Investment Advisory first reported a position in Novo Nordisk in Q2 2022 and held it in 4 quarters.
  • Vident Investment Advisory's Novo Nordisk position peaked at $1.89M in Q2 2023.
  • 1,307 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.